A translational approach to hypertensive heart disease

Hypertension

Volumn 55, Issue 1, 2010, Pages 1-8

  Díez, Javier ^a   Frohlich, Edward D ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; CASPASE 3; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN INHIBITOR;

BETA ADRENERGIC RECEPTOR BLOCKING; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART INFARCTION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPERTENSIVE HEART DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COLLAGEN; HEART DISEASES; HUMANS; HYPERTENSION; MODELS, BIOLOGICAL; MYOCARDIUM; MYOCYTES, CARDIAC; TRANSLATIONAL RESEARCH;

EID: 73849127738     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.141887     Document Type: Short Survey

References (53)

1. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fouad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Shub C. The heart in hypertension. N Engl J Med. 1992;327:998-1008.
2. Díez J, Gonzalez A, López B, Querejeta R. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med. 2005;2: 209-216.
3. Alpert NR, Mulieri LA. Increased myothermal economy of isometric force generation in compensated cardiac hypertrophy induced by pulmonary artery constriction in the rabbit: a characterization of heat liberation in normal and hypertrophied right ventricular papillary muscles. Circ Res. 1982;50:491-500.
4. Krauser DG, Devereux RB. Ventricular hypertrophy and hypertension: prognostic elements and implications for management. Herz. 2006;31: 305-316.
5. Petretto E, Sarwar R, Grieve I, Lu H, Kumaran MK, Muckett PJ, Mangion J, Schroen B, Benson M, Punjabi PP, Prasad SK, Pennell DJ, Kiesewetter C, Tasheva ES, Corpuz LM, Webb MD, Conrad GW, Kurtz TW, Kren V, Fischer J, Hubner N, Pinto YM, Pravenec M, Aitman TJ, Cook SA. Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet. 2008;40:546-552.
6. Arnett DK, Devereux RB, Rao DC, Li Na, Tang W, Kraemer R, Claas SA, Leon JM, Broeckel U. Novel genetic variants contributing to left ventricular hypertrophy: the HyperGEN Study J Hypertens. 2009;27: 1585-1593.
7. LeWinter MM, VanBuren P. Sarcomeric proteins in hypertrophied and failing myocardium: an overview. Heart Fail Rev. 2005;10:173-174.
8. Barry SP, Davidson SM, Townsend PA. Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol. 2008;40:2023-2039.
9. Giampietri C, Petrungaro S, Musumeci M, Coluccia P, Antonangeli F, De Cesaris P, Filippini A, Marano G, Ziparo E. c-Flip overexpression reduces cardiac hypertrophy in response to pressure overload. J Hypertens. 2008;26:1008-1016.
10. Arnett DK, de las Fuentes L, Broeckel U. Genes for left ventricular hypertrophy. Curr Hypertens Rep. 2004;6:36-41.
11. Pfeffer MA, Pfeffer JM. Ventricular remodeling and reduced survival after myocardial infarction. Circulation. 1987;75:IV93-IV97.
12. Díez J, Laviades C, Orbe J, Zalba G, López B, González A, Mayor G, Páramo JA, Beloqui O. The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J Hypertens. 2003;21:2085-2092.
13. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension. 2004;43:739-745.
14. Murdoch CE, Zhangm M, Cavem AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res. 2006;71:208215.
15. Varagic J, Frohlich ED, Díez J, Susic D, Ahn J, González A, López B. Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. Am J Physiol Heart Circ Physiol. 2006; 290:H1503-H1509.
16. González A, Ravassa S, López B, Loperena I, Querejeta R, Díez J. Apoptosis in hypertensive heart disease: a clinical approach. Curr Opin Cardiol. 2006;21:288294.
17. Narula J, Arbustini E, Chandrashekhar Y, Schwaiger M. Apoptosis and the systolic dysfunction in congestive heart failure: story of apoptosis interruptus and zombie myocytes. Cardiol Clin. 2001;19:113-126.
18. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568-575.
19. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993;27:341-348.
20. Schwartzkopff B, Motz W, Frenzel H, Voght M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial coronary arte-rioles in patients with arterial hypertension. Circulation. 1993;88: 993-1003.
21. McLenachan JM, Dargie JH. Ventricular arrhythmias in hypertensive left ventricular hypertrophy: relation to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens. 1990;3: 735-740.
22. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, Kottkamp H, Dhein S. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2005;91:166-170.
23. Feihl F, Liaudet L, Levy BI, Waeber B. Hypertension and microvascular remodelling. Cardiovasc Res. 2008;78:274-285.
24. Kelm M, Strauer BE. Coronary flow reserve measurements in hypertension. Med Clin North Am. 2004;88:99-113.
25. Kawano Y, Horio T, Matayoshi T, Kamide K. Masked hypertension: subtypes and target organ damage. Clin Exp Hypertens. 2008;30: 289-296.
26. Kuznetsova T, Staessen JA, Wang JG, Gasowski J, Nikitin Y, Ryabikov A, Fagard R. Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis. J Hum Hypertens. 2000;14:447-454.
27. Wu CK, Tsai CT, Hwang JJ, Luo JL, Juang JJ, Hsu KL, Lai LP, Lin JL, Tseng CD, Chiang FT. Renin-angiotensin system gene polymorphisms and diastolic heart failure. Eur J Clin Invest. 2008;38:789-797.
28. López B, González A, Lasarte JJ, Sarobe P, Borrás F, Díaz A, Barba J, Tomás L, Lozano E, Serrano M, Varo N, Beloqui O, Fortuño MA, Díez J. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens. 2005;23:625-632. (Pubitemid 40684722)
29. Alfakih K, Reid S, Hall A, Sivananthan MU. The assessment of left ventricular hypertrophy in hypertension. J Hypertens. 2006;24: 1223-1230.
30. Popović ZB, Kwon DH, Mishra M, Buakhamsri A, Greenberg NL, Thamilarasan M, Flamm SD, Thomas JD, Lever HM, Desai MY. Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiog-raphy and delayed hyperenhancement magnetic resonance imaging. J Am Soc Echocardiogr. 2008;21:1299-1305.
31. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574-1580.
32. Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, Doevendans PA, De Muinck E, Wellens HJ, Kemerink GJ, Reuteling-sperger CP, Heidendal GA. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet. 2000;356:209-212. (Pubitemid 30446976)
33. van den Borne SW, Isobe S, Verjans JW, Petrov A, Lovhaug D, Li P, Zandbergen HR, Ni Y, Frederik P, Zhou J, Arbo B, Rogstad A, Cuth-bertson A, Chettibi S, Reutelingsperger C, Blankesteijn WM, Smits JF, Daemen MJ, Zannad F, Vannan MA, Narula N, Pitt B, Hofstra L, Narula J. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol. 2008;52:2017-2028.
34. González A, López B, Ravassa S, Beaumont J, Arias T, Hermida N, Zudaire A, Díez J. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc Res. 2009;81:509-518.
35. González A, López B, Martín-Raymondi D, Lozano E, Varo N, Barba J, Serrano M, Díez J. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens. 2005;23:2297-2304.
36. Mosterd A, D'Agostino RB, Silbershatz H, Sytkowski PA, Kannel WB, Grobbee DE, Levy D. Trends in the prevalence of hypertension, antihy-pertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Eng J Med. 1999;340:1221-1227.
37. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
38. Tocci G, Sciaretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens. 2008;26:1477-1486.
39. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Fra-mingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation. 2009;119:3070-3077.
40. Varagic J, Frohlich ED, Susic D, Ahn J, Matavelli L, López B, Díez J. AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. Am J Physiol Heart Circ Physiol. 2008;294:H853-H858.
41. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the Trials of Hypertension Prevention (TOHP). BMJ. 2007;334:885-888.
42. Prisant LM. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents. Am J Med. 2008;121(8 suppl): S8-S15.
43. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myo-cardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388-1393.
44. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 2000;36:220-225. (Pubitemid 30626992)
45. González A, López B, Ravassa S, Querejeta R, Larman M, Díez J, Fortuño MA. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension. 2002;39:75-80.
46. López B, Querejeta R, Varo N, González A, Larman M, Martínez-Ubago JL, Díez J. Usefulness of serum carboxy-terminal propeptide of pro-collagen type I in assessment of the cardioreparative ability of antihyper-tensive treatment in hypertensive patients. Circulation. 2001;104: 286-291.
47. Díez J, Querejeta R, López B, González A, Larman M, Martínez-Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:2512-2517.
48. López B, González A, Beaumont J, Querejeta R, Larman M, Díez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50: 859-867.
49. Verma A, Solomon SD. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin N Am. 2009;93:647-664.
50. Luedde M, Katus HA, Frey N. Novel molecular targets in the treatment of cardiac hypertrophy. Recent Patents Cardiovasc Drug Discov. 2006; 1:1-20.
51. McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov. 2007;6: 617-635.
52. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358: 1370-1380.
53. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res. 2009;81:519-527.